Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. by Choudhary, Pratik et al.
Insulin Pump TherapyWith Automated
Insulin Suspension in Response to
Hypoglycemia
Reduction in nocturnal hypoglycemia in those at greatest risk
PRATIK CHOUDHARY, MD1
JOHN SHIN, PHD2
YONGYIN WANG, PHD2
MARK L. EVANS, MD3
PETER J. HAMMOND, FRCP4
DAVID KERR, FRCPE5
JAMES A.M. SHAW, PHD6
JOHN C. PICKUP, FRCPATH1
STEPHANIE A. AMIEL, FRCP1
OBJECTIVE—To evaluate a sensor-augmented insulin pump with a low glucose suspend
(LGS) feature that automatically suspends basal insulin delivery for up to 2 h in response to
sensor-detected hypoglycemia.
RESEARCH DESIGN ANDMETHODS—The LGS feature of the Paradigm Veo insulin
pump (Medtronic, Inc., Northridge, CA) was tested for 3 weeks in 31 adults with type 1 diabetes.
RESULTS—There were 166 episodes of LGS: 66% of daytime LGS episodes were terminated
within 10 min, and 20 episodes lasted the maximum 2 h. LGS use was associated with reduced
nocturnal duration #2.2 mmol/L in those in the highest quartile of nocturnal hypoglycemia at
baseline (median 46.2 vs. 1.8 min/day, P = 0.02 [LGS-OFF vs. LGS-ON]). Median sensor glucose
was 3.9 mmol/L after 2-h LGS and 8.2 mmol/L at 2 h after basal restart.
CONCLUSIONS—Use of an insulin pump with LGS was associated with reduced nocturnal
hypoglycemia in those at greatest risk and was well accepted by patients.
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C ontinuous glucose monitoring(CGM) can reduce HbA1c in type 1diabetes (1–3). Despite the use of
hypoglycemia alarms, most studies have
not demonstrated a signiﬁcant reduction
in hypoglycemia, and prolonged noctur-
nal hypoglycemia occurs frequently (4).
This may be because patients sleep
throughmany of the alarms (5) and insulin
delivery continues during hypoglycemia.
We report a user evaluation of the
Paradigm Veo insulin pump (Medtronic,
Inc., Northridge, CA), which can auto-
matically suspend basal insulin delivery
for up to 2 h in the event of CGM-detected
hypoglycemia, thus reducing the dura-
tion of hypoglycemia.
RESEARCH DESIGN AND
METHODS—The Veo was evaluated
by 31 patients (10 men) with type 1
diabetes (mean age, 41.9 6 10.6 years)
from six U.K. centers. Regional ethics
committees approved the study, and pa-
tients provided informed consent. The
Veo system has alarms for hypoglycemia,
predicted hypoglycemia, rate-of-change
of glucose, and, uniquely, a low glucose
suspend (LGS) feature that is activated
when sensor glucose reaches a glucose
threshold set by the user. An alarm
sounds, and if the user does not respond,
basal insulin delivery is suspended for a
maximum of 2 h, after which basal insulin
delivery is resumed at the programmed
rate. The patient may resume basal insulin
delivery at any point.
During a 2-week run-in, CGM was
used with only predictive, rate-of-change,
high and low alerts active (LGS-OFF).
LGS was then activated for 3 weeks (LGS-
ON). We evaluated the response to LGS
and compared hypoglycemia exposure
and mean blood glucose during LGS-
OFF and LGS-ON. Patients were divided
into four equal groups (quartiles) by the
duration of hypoglycemia during the run-in
period, because we wished to test the hy-
pothesis that those with the most hypo-
glycemia at baseline (without LGS) would
have the greatest beneﬁt with LGS. Hy-
poglycemia was deﬁned as the lower limit
of detection of the sensor (2.2 mmol/L)
(6). The glucose threshold to trigger LGS
was individualized (median 2.4 [range
2.2–3.5] mmol/L). Night was deﬁned as
0000–0800 h. Treatment satisfaction ques-
tionnaires were completed at study end.
Data were compared using the Student
t test, except for skewed data (hypoglyce-
mia duration), which were compared with
the Wilcoxon test. Values are mean 6 SD
or median (range).
RESULTS—Two subjects withdrew
during run-in due to difﬁculties using
sensors, and one subject failed to acti-
vate the LGS. There were 166 LGS ep-
isodes in 25 of 28 (89%) completers
(mean 1.9 LGS events/week), of which
76% occurred during daytime, and 55%
were terminated within 10 min. LGS con-
tinued for themaximum 2 h in 20 episodes
(12%), 75% of which were nocturnal. Of
20 completed 2-h suspends, 7 (35%) had
no patient response throughout. In the
remaining 13 (65%), patients responded
to the alarm but elected to continue LGS for
2 h. Mean response time to the LGS alarm
was longer at night compared with day
(63.268.2 vs. 17.462.7min,P,0.001).
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LGS use was associated with signiﬁ-
cant reduction in the duration of nocturnal
hypoglycemia (#2.2 mmol/L) in those in
the highest quartile of hypoglycemia dura-
tion at baseline: median 46.2 (36.6–191.4)
vs. 1.8 (0.0–45) min/day (P = 0.02; LGS-
OFF vs. LGS-ON) (Fig. 1) and mean
75.1 6 54 vs. 10.2 6 18 min/day (P =
0.02). Mean sensor glucose was not differ-
ent with LGS-OFF or LGS-ON (6.4 6 1.3
vs. 6.66 1.1 mmol/L, P = 0.26). After the
20 complete 2-h LGS episodes, median
sensor glucose was 3.9 (2.4–14.2) mmol/L
at the restart of basal insulin and was 8.2
(3.3–17.3) mmol/L 2 h after restart. Car-
bohydrate ingestion was not recorded.
Concomitant (within 15 min of LGS)
capillary glucose values were available for
43 of 166 episodes (25.9%) of LGS. These
were.5 mmol/L in 13 episodes and.10
mmol/L in 4, although we do not know if
any carbohydrate was ingested before
testing. LGS was terminated within 2 min
in all four episodes with capillary glucose
.10 mmol/L, with sensor error alerts in
two of these.
All subjects reported ﬁnding LGS
“useful,” and 93% reported feeling more
secure at night, with reduced anxiety, and
wanted to continue using it.
CONCLUSIONS—These data suggest
that LGS has the potential to reduce
nocturnal hypoglycemia in patients with
type 1 diabetes at the highest risk. This is
similar to results with insulin pump
therapy providing the greatest reduction
in hypoglycemia in those with the most
hypoglycemia at baseline (7).
The risk of ketosis and hyperglycemia
after the 2-h suspension of insulin
delivery is low (8,9). In our study, median
sensor glucose after 2 h of LGS was 3.9
(2.4–14.2) mmol/L. We could not deter-
mine if carbohydrate had been consumed
during the LGS. There was no evidence of
deterioration of overall glucose control
with LGS activated.
Patients took longer to respond to the
LGS alarm at night, and 75% of com-
pleted 2-h LGS events occurred overnight.
This may relate to the combined effects
of sleep and hypoglycemia on alertness/
arousability, and reduced counter-
regulatory responses during sleep (10).
Most daytime LGS episodes were termi-
nated by users within 10 min.
The sensor may under-report glu-
cose, particularly during nocturnal hypo-
glycemia and in view of the lag between
interstitial and capillary glucose (11). Al-
though the lowest displayed sensor value
is 2.2 mmol/L, the Veo algorithm has im-
proved hypoglycemia detection com-
pared with previous algorithms, with a
mean absolute relative difference between
2.2 and 4.4 mmol/L reduced from 24.8
to19.5% (12). We set the LGS threshold
low (mean, 2.4 mmol/L), and a higher
threshold may have led to greater reduc-
tion in hypoglycemia. Our study could
not determine rates of false-positive
LGS: 4 of 43 LGS had a capillary glucose
reading within 15 min.10 mmol/L, and
2 of these were preceded by sensor error
alerts. However, these capillary readings
may be biased toward episodes when the
patient thought the LGS was erroneous.
LGS reduces anxiety about nocturnal
hypoglycemia. Randomized controlled
trials that evaluate hypoglycemia and
quality-of-life in type 1 diabetes using
LGS pumps compared with insulin pump
therapy alone, with or without CGM, are
now needed. This is the ﬁrst system that
modulates insulin delivery in response to
glucose levels without human interven-
tion and is an important step toward
clinically available closed-loop systems.
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